Search
Cupric sulfate
go.drugbank.com/drugs/DB06778ApprovedSome of its secondary uses are as a raw material in the preparation of other copper compounds, as a reagent in analytic chemistry, as an electrolyte for batteries and electroplating baths, and in medical … The average daily intake of copper in the USA is approximately 1 mg Cu with the diet being a primary source [A32221].
Mixtures: One A Day Advance Adults, One-A-day Advance Men'sCategories: Compounds used in a research, industrial, or household settingGemfibrozil
go.drugbank.com/drugs/DB01241ApprovedInvestigational[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. … [L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]
International brands: Gen-FibroPiroxicam
go.drugbank.com/drugs/DB00554ApprovedInvestigationalA cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea
Synonyms: 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxidProducts: PIROXICAM EG, ILMODOL DOLORE E INFIAMMAZIONERemestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnBased on its tolerability and safety profile, remestemcel-L is a promising alternative to second-line immunosuppressive agents [A31818]. … with first-line therapies, putting them in a risk for poor outcomes and creating a significant clinical challenge [A31818].
Synonyms: Remestemcel-LTriethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigational[A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and … TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925.
Categories: Compounds used in a research, industrial, or household settingGabapentin
go.drugbank.com/drugs/DB00996ApprovedInvestigationalGabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. … making it unlikely to participate in pharmacokinetic drug interactions.
Mixtures: GAVINDO NProducts: GABAPENTIN EG, GABAPENTIN AL 800MGNilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigational), another tyrosine kinase inhibitor used as a first-line treatment for CML. … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexEtoricoxib
go.drugbank.com/drugs/DB01628ApprovedInvestigationalWithdrawnIt is approved in more than 60 countries worldwide but not in the US. … Etoricoxib is a new COX-2 selective inhibitor.
Products: ETORICOXIB EG, ETORICOXIB AL 60MGDorzolamide
go.drugbank.com/drugs/DB00869ApprovedInvestigational[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. … [A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]
Mixtures: Tim-Dor-Lat, Tim-Brim-Dor-LatProducts: DORZOLAMID AL 20 MG/ML, DORZOLAMID 1A PHARM20MG/MLRopeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242005] Ropeginterferon alfa-2b is a next-generation mono-pegylated type I interferon produced from proline-IFN-α-2b in _Escherichia coli_ that has high tolerability and a long half-life. … [A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials.
Products: BESREMi Pen